Cargando…

Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance

BACKGROUND: Successful management of chronic human immunodeficiency virus type 1 (HIV-1) infection with a cocktail of antiretroviral medications can be negatively affected by the presence of drug resistant mutations in the viral targets. These targets include the HIV-1 protease (PR) and reverse tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Masso, Majid, Vaisman, Iosif I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849442/
https://www.ncbi.nlm.nih.gov/pubmed/24268064
http://dx.doi.org/10.1186/1471-2164-14-S4-S3
_version_ 1782293925901369344
author Masso, Majid
Vaisman, Iosif I
author_facet Masso, Majid
Vaisman, Iosif I
author_sort Masso, Majid
collection PubMed
description BACKGROUND: Successful management of chronic human immunodeficiency virus type 1 (HIV-1) infection with a cocktail of antiretroviral medications can be negatively affected by the presence of drug resistant mutations in the viral targets. These targets include the HIV-1 protease (PR) and reverse transcriptase (RT) proteins, for which a number of inhibitors are available on the market and routinely prescribed. Protein mutational patterns are associated with varying degrees of resistance to their respective inhibitors, with extremes that can range from continued susceptibility to cross-resistance across all drugs. RESULTS: Here we implement statistical learning algorithms to develop structure- and sequence-based models for systematically predicting the effects of mutations in the PR and RT proteins on resistance to each of eight and eleven inhibitors, respectively. Employing a four-body statistical potential, mutant proteins are represented as feature vectors whose components quantify relative environmental perturbations at amino acid residue positions in the respective target structures upon mutation. Two approaches are implemented in developing sequence-based models, based on use of either relative frequencies or counts of n-grams, to generate vectors for representing mutant proteins. To the best of our knowledge, this is the first reported study on structure- and sequence-based predictive models of HIV-1 PR and RT drug resistance developed by implementing a four-body statistical potential and n-grams, respectively, to generate mutant attribute vectors. Performance of the learning methods is evaluated on the basis of tenfold cross-validation, using previously assayed and publicly available in vitro data relating mutational patterns in the targets to quantified inhibitor susceptibility changes. CONCLUSION: Overall performance results are competitive with those of a previously published study utilizing a sequence-based strategy, while our structure- and sequence-based models provide orthogonal and complementary prediction methodologies, respectively. In a novel application, we describe a technique for identifying every possible pair of RT inhibitors as either potentially effective together as part of a cocktail, or a combination that is to be avoided.
format Online
Article
Text
id pubmed-3849442
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38494422013-12-06 Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance Masso, Majid Vaisman, Iosif I BMC Genomics Research BACKGROUND: Successful management of chronic human immunodeficiency virus type 1 (HIV-1) infection with a cocktail of antiretroviral medications can be negatively affected by the presence of drug resistant mutations in the viral targets. These targets include the HIV-1 protease (PR) and reverse transcriptase (RT) proteins, for which a number of inhibitors are available on the market and routinely prescribed. Protein mutational patterns are associated with varying degrees of resistance to their respective inhibitors, with extremes that can range from continued susceptibility to cross-resistance across all drugs. RESULTS: Here we implement statistical learning algorithms to develop structure- and sequence-based models for systematically predicting the effects of mutations in the PR and RT proteins on resistance to each of eight and eleven inhibitors, respectively. Employing a four-body statistical potential, mutant proteins are represented as feature vectors whose components quantify relative environmental perturbations at amino acid residue positions in the respective target structures upon mutation. Two approaches are implemented in developing sequence-based models, based on use of either relative frequencies or counts of n-grams, to generate vectors for representing mutant proteins. To the best of our knowledge, this is the first reported study on structure- and sequence-based predictive models of HIV-1 PR and RT drug resistance developed by implementing a four-body statistical potential and n-grams, respectively, to generate mutant attribute vectors. Performance of the learning methods is evaluated on the basis of tenfold cross-validation, using previously assayed and publicly available in vitro data relating mutational patterns in the targets to quantified inhibitor susceptibility changes. CONCLUSION: Overall performance results are competitive with those of a previously published study utilizing a sequence-based strategy, while our structure- and sequence-based models provide orthogonal and complementary prediction methodologies, respectively. In a novel application, we describe a technique for identifying every possible pair of RT inhibitors as either potentially effective together as part of a cocktail, or a combination that is to be avoided. BioMed Central 2013-10-01 /pmc/articles/PMC3849442/ /pubmed/24268064 http://dx.doi.org/10.1186/1471-2164-14-S4-S3 Text en Copyright © 2013 Masso et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Masso, Majid
Vaisman, Iosif I
Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
title Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
title_full Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
title_fullStr Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
title_full_unstemmed Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
title_short Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
title_sort sequence and structure based models of hiv-1 protease and reverse transcriptase drug resistance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849442/
https://www.ncbi.nlm.nih.gov/pubmed/24268064
http://dx.doi.org/10.1186/1471-2164-14-S4-S3
work_keys_str_mv AT massomajid sequenceandstructurebasedmodelsofhiv1proteaseandreversetranscriptasedrugresistance
AT vaismaniosifi sequenceandstructurebasedmodelsofhiv1proteaseandreversetranscriptasedrugresistance